<DOC>
	<DOCNO>NCT01129557</DOCNO>
	<brief_summary>Primary Hypothesis : Aldosterone breakthrough occur far low frequency renin inhibition ( 0-10 % 9 month ) , alone combination ARB , compare conventional ARB therapy ( 35-45 % 9 month ) . The investigator hypothesize aldosterone breakthrough occurs due accumulation active precursor substance , notably angiotensin II , produce response conventional RAAS blockade ACEinhibitors ARBs . The investigator believe direct renin inhibition ( DRI ) minimize accumulation therefore significantly low possibly eliminate breakthrough effect . Interruption renin-angiotensin-aldosterone system ( RAAS ) angiotensin-converting enzyme inhibitor ( ACE-Is ) angiotensin receptor blocker ( ARBs ) , alone combination , become leading therapy slow progression chronic heart kidney disease . Both type drug inhibit formation aldosterone , hormone , show harmful effect patient chronic heart kidney disorder . This treatment effective perfect since , even initial improvement , many patient become bad long term . This may due unexpected increase aldosterone , phenomenon call `` aldosterone breakthrough . '' The purpose study find whether use direct renin inhibitor ( DRI ) alone , combination angiotensin receptor blocker ( ARB ) , lessen occurrence aldosterone breakthrough since direct renin inhibitor inhibit formation aldosterone early step . This study compare effectiveness add Diovan ( valsartan ) Tekturna ( aliskiren ) combination Diovan Tekturna usual antihypertensive treatment . The investigator follow blood pressure , aldosterone level , urinary protein level 9 month evaluate therapy effective treat hypertension patient proteinuric kidney disease .</brief_summary>
	<brief_title>Aldosterone Breakthrough During Diovan , Tekturna , Combination Therapy Patients With Proteinuric Kidney Disease</brief_title>
	<detailed_description>This randomize , open-label , three-arm study compare Diovan ( valsartan , ARB ) , Tekturna ( aliskiren , DRI ) , combination valsartan + aliskiren ( i.e . ARB + DRI ) . One hundred twenty subject ( 40 per arm ) treat Tekturna , Diovan , combination drug 9 month top usual antihypertensive treatment . Changes urinary aldosterone excretion monitor therapy measure incidence aldosterone breakthrough , define sustained positive change baseline urinary aldosterone excretion completion 9-month study period . This frequency measure compare ARB , DRI , ARB + DRI therapy . Changes urinary protein excretion also monitor alongside urinary aldosterone level determine whether aldosterone breakthrough associate refractory proteinuria . This innovative study first ( 1 ) examine aldosterone breakthrough DRI therapy , ( 2 ) explore whether addition DRI ARB protect aldosterone breakthrough . In addition , first study examine whether DRI therapy ( alone combination ARB ) effective therapy hypertension patient non-diabetic proteinuric kidney disease .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Nephrosclerosis</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Proteinuria &gt; 300 mg/day Normal mildly reduce kidney function ( eGFR &gt; 45 ml/min/1.73m2 ) Systolic blood pressure &gt; 130 mm Hg Diastolic blood pressure &gt; 70 mm Hg Diagnoses diabetic nephropathy , hypertensive nephrosclerosis , IgA nephropathy , focal segmental glomerulosclerosis , membranoproliferative glomerulonephritis , membranous nephropathy , fibrillary glomerulonephritis , obesityassociated glomerulopathy Concomitant use cyclosporine ( interact aliskiren ) Inability undergo 6 week washout period already RAASblocking drug ( ) ( include renin inhibitor , ACEinhibitor , ARB , mineralocorticoid receptor blocker ) eGFR &lt; 45 ml/min/1.73m2 Urine protein excretion &lt; 300 mg/day Serum K &gt; 5.0 mEq/l Systolic blood pressure &gt; 170 mm Hg &lt; 130 mm Hg washout period Diastolic blood pressure &gt; 110 mm Hg &lt; 70 mm Hg washout period Congestive heart failure NYHA class III IV History cardiovascular event ( stroke , TIA , MI , unstable angina , CABG , PCI , CHF hospitalization ) 3 month prior study visit 1 2nd 3rd degree heart block without pacemaker uncontrolled arrhythmia Clinically significant valvular disease Known renal artery stenosis Any surgical medical condition might significantly alter pharmacokinetics study drug ( n.b . bariatric surgery &gt; 6 month prior visit 1 exclusion ) History evidence drug alcohol abuse within last 12 month Any concurrent life threaten condition life expectancy le 2 year Pregnant nursing ( lactate ) woman Women childbearing potential unless postmenopausal least 1 year , surgically sterile , use effective method contraception define local health authority</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>